{"id":1848,"date":"2022-11-16T13:50:27","date_gmt":"2022-11-16T10:50:27","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=1848"},"modified":"2022-11-16T14:31:01","modified_gmt":"2022-11-16T11:31:01","slug":"yaklasik-40-bin-kisiden-elde-edilen-veriler-turkiyenin-akciger-kanseri-risk-haritasini-olusturacak","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=1848","title":{"rendered":"Yakla\u015f\u0131k 40 Bin Ki\u015fiden Elde Edilen Veriler, T\u00fcrkiye\u2019nin Akci\u011fer Kanseri Risk Haritas\u0131n\u0131 Olu\u015fturacak!"},"content":{"rendered":"

T\u00fcrk T\u0131bbi Onkoloji Derne\u011fi\u2019nin (TTOD) toplum bilgilendirme platformu arac\u0131l\u0131\u011f\u0131yla, AstraZeneca T\u00fcrkiye\u2019nin ko\u015fulsuz deste\u011fi ile akci\u011fer kanseri risk fakt\u00f6rleri hakk\u0131nda toplumu bilgilendirmek amac\u0131yla hayata ge\u00e7irdi\u011fi \u2018Akci\u011ferimizi Okuyoruz\u2019 internet platformundan elde edilen sonu\u00e7lar kamuoyu ile payla\u015f\u0131ld\u0131. Platform \u00fczerindeki sorular\u0131 cevaplayan ki\u015filerin verilerine g\u00f6re en fazla 18 – 49 ya\u015f grubundaki ki\u015filer ve her iki kat\u0131l\u0131mc\u0131dan biri sigara i\u00e7iyor. Akci\u011fer hastal\u0131\u011f\u0131n\u0131n erkeklerde daha fazla g\u00f6r\u00fcld\u00fc\u011f\u00fcn\u00fc de ortaya \u00e7\u0131karan sonu\u00e7lara g\u00f6re kronik obstr\u00fcktif akci\u011fer hastal\u0131\u011f\u0131n\u0131n (KOAH) cinsiyete g\u00f6re da\u011f\u0131l\u0131m\u0131nda ise erkek ve kad\u0131n oranlar\u0131 birbirine yak\u0131n \u00e7\u0131kt\u0131.\u00a0\u00a0\u00a0\u00a0 <\/strong><\/p>\n

D\u00fcnya genelinde kanser hastal\u0131klar\u0131 aras\u0131nda ilk s\u0131ralarda yer alan akci\u011fer kanserinin ba\u015flang\u0131\u00e7 evresinde ortaya \u00e7\u0131kan belirti ve bulgular\u0131 \u00e7o\u011funlukla fark edilmiyor. \u00d6zellikle sigara kullanan ki\u015filerde \u00f6ks\u00fcr\u00fck gibi \u00f6nemli belirtiler de b\u00fcy\u00fck oranda dikkate al\u0131nmad\u0131\u011f\u0131ndan bu durum akci\u011fer kanserinin \u00e7ok ge\u00e7 evrelerde fark edilmesine neden oluyor ve tedavi s\u00fcrecini olduk\u00e7a zorla\u015ft\u0131r\u0131yor.<\/p>\n

Bu ger\u00e7ekten yola \u00e7\u0131kan T\u00fcrk T\u0131bbi Onkoloji Derne\u011fi (TTOD), AstraZeneca T\u00fcrkiye\u2019nin ko\u015fulsuz deste\u011fi ile 2020 y\u0131l\u0131nda \u2018Akci\u011ferimizi Okuyoruz\u2019 internet platformunu, akci\u011fer kanseri risk fakt\u00f6rleri hakk\u0131nda toplumu bilgilendirmek amac\u0131yla hayata ge\u00e7irdi.<\/p>\n

\u2018Akci\u011ferimizi Okuyoruz\u2019 platformu \u00fczerinden bug\u00fcne kadar yakla\u015f\u0131k 40 bin ki\u015fiden elde edilen ve akci\u011fer kanserinde erken te\u015fhis konusunda toplumda fark\u0131ndal\u0131k yaratacak veriler; T\u00fcrk T\u0131bbi Onkoloji Derne\u011fi Ba\u015fkan\u0131 Prof. Dr. Murat Din\u00e7er, T\u00fcrk T\u0131bbi Onkoloji Derne\u011fi Genel Sekreteri Prof. Dr. \u00d6zlem S\u00f6nmez, Halk Sa\u011fl\u0131\u011f\u0131 Anabilim Dal\u0131 \u00d6\u011fretim \u00dcyesi Prof. Dr. G\u00fcl Erg\u00f6r ve AstraZeneca T\u00fcrkiye \u00dclke Ba\u015fkan\u0131 Ecz. Serkan Bar\u0131\u015f\u2019\u0131n kat\u0131l\u0131mlar\u0131 ile d\u00fczenlenen bas\u0131n toplant\u0131s\u0131nda kamuoyu ile payla\u015f\u0131ld\u0131.<\/p>\n

81 ilin tamam\u0131ndan kat\u0131l\u0131m sa\u011fland\u0131 <\/strong><\/p>\n

\u2018Akci\u011ferimizi Okuyoruz\u2019 internet platformu \u00fczerinden T\u00fcrkiye genelinde 81 ilde ya\u015fayan 38 bin 623 ki\u015fiden anonim \u015fekilde elde edilen verilere g\u00f6re kat\u0131l\u0131mc\u0131lar\u0131n y\u00fczde 63,4\u2019\u00fc erkeklerden, y\u00fczde 36,6\u2019s\u0131 ise kad\u0131nlardan olu\u015ftu. Kat\u0131l\u0131mc\u0131lar\u0131n y\u00fczde 52,5\u2019ini 30 \u2013 49 ya\u015f aras\u0131 ki\u015filer olu\u015ftururken bu grubu s\u0131ras\u0131yla y\u00fczde 31,5 ile 50 \u2013 69 ya\u015f aras\u0131, y\u00fczde 13 ile 18 – 29 ya\u015f aras\u0131 ve y\u00fczde 3 ile 70 ya\u015f \u00fczeri ki\u015filer takip etti. Kat\u0131l\u0131mc\u0131lar\u0131n ya\u015fad\u0131\u011f\u0131 illere g\u00f6re da\u011f\u0131l\u0131mda ilk s\u0131rada y\u00fczde 24,6 ile \u0130stanbul yer ald\u0131. Ankara y\u00fczde 10,8 ile ikinci olurken \u0130zmir y\u00fczde 9,4 ile \u00fc\u00e7\u00fcnc\u00fc oldu.<\/p>\n

\"\"<\/p>\n

Akci\u011fer hastal\u0131\u011f\u0131 erkeklerde daha fazla g\u00f6r\u00fcl\u00fcyor<\/strong><\/p>\n

Platform \u00fczerinden bilgilerini payla\u015fanlar\u0131n y\u00fczde 6,3\u2019\u00fc kronik obstr\u00fcktif akci\u011fer hastas\u0131 (KOAH) ve y\u00fczde 0,8\u2019i akci\u011fer kanseri hastas\u0131 olduklar\u0131n\u0131 s\u00f6yledi.\u00a0 Akci\u011fer kanseri varl\u0131\u011f\u0131n\u0131n cinsiyete g\u00f6re da\u011f\u0131l\u0131m\u0131nda kat\u0131l\u0131mc\u0131 erkeklerin y\u00fczde 1\u2019i akci\u011fer kanser hastas\u0131 olduklar\u0131n\u0131 ifade ederken, kad\u0131nlar\u0131n y\u00fczde 0,6\u2019s\u0131 akci\u011fer kanseri hastas\u0131 olduklar\u0131n\u0131 s\u00f6yledi. KOAH varl\u0131\u011f\u0131n\u0131n cinsiyete g\u00f6re da\u011f\u0131l\u0131m\u0131nda ise erkek ve kad\u0131n oranlar\u0131 birbirine yak\u0131n \u00e7\u0131kt\u0131. Buna g\u00f6re erkeklerin y\u00fczde 6,5\u2019i kad\u0131nlar\u0131n ise y\u00fczde 6,3\u2019\u00fc KOAH hastas\u0131 olduklar\u0131n\u0131 belirtti.<\/p>\n

\"\"Ya\u015f gruplar\u0131na g\u00f6re akci\u011fer kanseri varl\u0131\u011f\u0131nda y\u00fczde 3,6 ile 70 ya\u015f \u00fczeri ki\u015filer ilk s\u0131rada. Bunu y\u00fczde 1,4 ile 50 \u2013 69 ya\u015f aras\u0131, y\u00fczde 0,4 ile 30 \u2013 49 ya\u015f aras\u0131 ve y\u00fczde 0,7 ile 18 \u2013 29 ya\u015f aras\u0131 ki\u015filer izledi. KOAH\u2019\u0131n ise en \u00e7ok y\u00fczde 19,5 ile 70 ya\u015f \u00fczeri ki\u015filerde g\u00f6r\u00fcld\u00fc\u011f\u00fc ortaya \u00e7\u0131kt\u0131. Bunu y\u00fczde 11,3 ile 50 \u2013 69 ya\u015f aras\u0131, y\u00fczde 3,5 ile 30 \u2013 49 ya\u015f aras\u0131 ve y\u00fczde 2,2 ile 18 \u2013 29 ya\u015f aras\u0131 ki\u015filer takip etti.<\/p>\n

Kat\u0131l\u0131mc\u0131larda hastal\u0131k \u00f6yk\u00fcs\u00fcne bak\u0131ld\u0131\u011f\u0131nda ise her d\u00f6rt ki\u015fiden biri (y\u00fczde 25,3) ailede akci\u011fer kanseri oldu\u011funu belirtti.<\/p>\n

\"\"<\/p>\n

Erkeklerde sigara i\u00e7enlerin oran\u0131 daha fazla<\/strong><\/p>\n

Neredeyse her iki ki\u015fiden biri (y\u00fczde 48,4) sigara i\u00e7ti\u011fini belirtirken i\u00e7meyenlerin oran\u0131 y\u00fczde 26,5 oldu. Sigaray\u0131 b\u0131rakt\u0131\u011f\u0131n\u0131 s\u00f6yleyenlerin oran\u0131 ise y\u00fczde 18,2. Erkeklerde sigara i\u00e7tiklerini s\u00f6yleyenlerin oran\u0131 y\u00fczde 51,7 olurken kad\u0131nlarda bu oran y\u00fczde 42,8 oldu. Ortaya \u00e7\u0131kan bir di\u011fer \u00f6nemli sonu\u00e7 ise kad\u0131nlar\u0131n erkeklere k\u0131yasla \u00e7ok daha fazla pasif i\u00e7ici konumda olmas\u0131. Erkeklerin y\u00fczde 4,8\u2019i pasif i\u00e7ici oldu\u011funu ifade ederken kad\u0131nlarda bu oran y\u00fczde 10,3\u2019e \u00e7\u0131k\u0131yor.<\/p>\n

\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Sigaray\u0131 b\u0131rakmadan \u00f6nce i\u00e7me s\u00fcresi ortalama 20 y\u0131l<\/strong><\/p>\n

\"\"Halen sigara i\u00e7enlerin i\u00e7me s\u00fcresini de ortaya \u00e7\u0131karan sonu\u00e7lara g\u00f6re kat\u0131l\u0131mc\u0131lar\u0131n y\u00fczde 31,3\u2019\u00fc 20 \u2013 29 y\u0131ld\u0131r sigara i\u00e7ti\u011fini s\u00f6yledi. Y\u00fczde 26,8\u2019i 10 \u2013 19 y\u0131l, y\u00fczde 16,7\u2019si 30 \u2013 39 y\u0131l, y\u00fczde 14,6\u2019s\u0131 ise 1 \u2013 9 y\u0131l sigara i\u00e7tiklerini belirtti. 40 y\u0131ldan fazla s\u00fcre sigara i\u00e7tiklerini s\u00f6yleyenlerin oran\u0131 ise y\u00fczde 10,6.\u00a0 Kat\u0131l\u0131mc\u0131lar\u0131n y\u00fczde 80,1\u2019i g\u00fcnde 1 \u2013 20, y\u00fczde 18,3\u2019\u00fc ise 21 \u2013 40 adet sigara i\u00e7ti\u011fini s\u00f6ylerken toplam sonu\u00e7lara g\u00f6re g\u00fcnde ortalama 15 sigara i\u00e7iliyor. Sigaray\u0131 b\u0131rakanlarda ortalama b\u0131rakma s\u00fcresi 5 y\u0131l oldu. B\u0131rakmadan \u00f6nce i\u00e7me s\u00fcresi ortalama 20 y\u0131l.<\/p>\n

 <\/p>\n

Hava kirlili\u011fi risk fakt\u00f6rlerinin ba\u015f\u0131nda geliyor<\/strong><\/p>\n

Verilere g\u00f6re sigara haricinde akci\u011fer kanseri hastal\u0131\u011f\u0131na neden olabilecek \u00e7e\u015fitli risklere maruz kal\u0131m durumunda ilk s\u0131rada y\u00fczde 7,1 ile hava kirlili\u011fi yer ald\u0131. Bunu s\u0131ras\u0131yla y\u00fczde 3,3 ile verem, y\u00fczde 2,9 ile elementler (a\u011f\u0131r metaller, petrol \u00fcr\u00fcnleri vb.) ve radyoterapi, y\u00fczde 1,4 ile asbest ve y\u00fczde 0,6 ile radon takip etti.<\/p>\n

Akci\u011fer kanserine sebep olabilecek risk fakt\u00f6rlerini ve bu fakt\u00f6rlerden hangilerine sahip oldu\u011funuzu \u00f6\u011frenebilece\u011finiz platforma T\u00fcrk T\u0131bbi Onkoloji Derne\u011fi (TTOD) toplum bilgilendirme platformu arac\u0131l\u0131\u011f\u0131yla https:\/\/www.akcigerimiziokuyoruz.com\/ adresi \u00fczerinden ula\u015fabilirsiniz.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

T\u00fcrk T\u0131bbi Onkoloji Derne\u011fi\u2019nin (TTOD) toplum bilgilendirme platformu arac\u0131l\u0131\u011f\u0131yla, AstraZeneca T\u00fcrkiye\u2019nin ko\u015fulsuz deste\u011fi ile akci\u011fer kanseri risk fakt\u00f6rleri hakk\u0131nda toplumu bilgilendirmek amac\u0131yla hayata ge\u00e7irdi\u011fi \u2018Akci\u011ferimizi Okuyoruz\u2019 internet platformundan elde edilen sonu\u00e7lar kamuoyu ile payla\u015f\u0131ld\u0131. Platform \u00fczerindeki sorular\u0131 cevaplayan ki\u015filerin verilerine g\u00f6re en fazla 18 – 49 ya\u015f grubundaki ki\u015filer ve her iki kat\u0131l\u0131mc\u0131dan biri sigara …<\/p>\n","protected":false},"author":1,"featured_media":1849,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,3],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/1848"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1848"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/1848\/revisions"}],"predecessor-version":[{"id":1854,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/1848\/revisions\/1854"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/1849"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}